Neoadjuvant treatment shows organ preservation in solid tumors with mismatch repair deficiency, suggesting effective nonoperative management strategies.
Among patients with early-stage dMMR solid tumors that were amenable to curative-intent surgery, neoadjuvant PD-1 blockade led to organ preservation in a high proportion of patients. (Funded by Swim Across America and others; ClinicalTrials.gov number, NCT04165772.).
No takes yet. Share an insight, caveat, or question.
Cercek et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: